CD274 and neoplasm: Immune checkpoint therapy has become an indispensable treatment modality today, and programmed death ligand-1 (PD-L1) and tumor mutational burden have been widely used as biomarkers to assess the suitability of patients for immunotherapy; however, biomarkers of ICIs therapy in NSCLC remain elusive [8,9].